The effect of Syk inhibition has been tested with fostamatinib (R406), a kinase inhibitor with limited specificity to Syk, demonstrating induction of apoptosis and blockade of chemokine-induced migration of CLL cells [11, 12] Fostamatinib has been clinically evaluated in CLL and other B cell malignancies with a hint of efficacy in these diseases [13, 14]. This evidence concerns the gene SYK and B-cell chronic lymphocytic leukemia.